is a biopharmaceutical company that specializes in researching, developing and commercializing innovative medicines. The company has achieved an impressive performance, outperforming the S&P 500 by a significant 45.5 per cent. It’s the top performer of our list. Gilead Sciences generates 60 per cent of its revenue from HIV treatments, which form a resilient portion of its portfolio.
Investors are advised to do further research before investing in any of the companies listed in the accompanying table.Be smart with your money. Get the latest investing insights delivered right to your inbox three times a week, with the Globe Investor newsletter.
대한민국 최근 뉴스, 대한민국 헤드 라인
Similar News:다른 뉴스 소스에서 수집한 이와 유사한 뉴스 기사를 읽을 수도 있습니다.
S&P/TSX composite up in mid-morning trading on health care, energy stocksCanada's main stock index rose in late-morning trading, as health care and energy stocks trended upward.
더 많은 것을 읽으십시오 »